The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a phase II trial.
Carlo Buonerba
No relevant relationships to disclose
Margaret Ottaviano
No relevant relationships to disclose
Piera Federico
No relevant relationships to disclose
Filomena Calabrese
No relevant relationships to disclose
Claudia Von Arx
No relevant relationships to disclose
Simona Iaccarino
No relevant relationships to disclose
Lucia Nappi
No relevant relationships to disclose
Irene Tucci
No relevant relationships to disclose
Giuseppe di Lorenzo
No relevant relationships to disclose
Elide Matano
No relevant relationships to disclose
Vincenzo Damiano
No relevant relationships to disclose
Giovannella Palmieri
No relevant relationships to disclose